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LETTER TO THE EDITOR
Erythema Multiforme after Radiotherapy with 
5-fluorouracil Chemotherapy in a Rectal Cancer Patient
Jung Hyun Han, M.D., Sook Jung Yun, M.D., Taek-Keun Nam, M.D.
1, Yoo-Duk Choi, M.D.
2, 
Jee-Bum Lee, M.D., Seong-Jin Kim, M.D.
Departments of Dermatology, 
1Radiation Oncology and 
2Pathology, Chonnam National University Medical School, Gwangju, Korea
Dear Editor:
Erythema multiforme (EM) is commonly induced by drugs, 
such as anticonvulsants, antibiotics, and allopurinol. 
Other potential triggers include herpes virus infection, 
Mycoplasma  pneumonia, malignancy, connective tissue 
diseases, and radiotherapy. There have been rare reports 
of EM induced by 5-fluorouracil (5-FU) with or without 
radiotherapy
1-3.
 We report a case of a rare skin reaction 
after chemotherapy with 5-FU and radiotherapy in a 
patient with rectal cancer. The condition was diagnosed as 
EM secondary to the interaction of radiotherapy and 
chemotherapy.
A 54-year-old man presented with pruritic, erythematous 
targetoid papules, and confluent macules on the buttocks, 
dorsum of the hands, and the ears for 5 days. Six months 
earlier, the patient had undergone surgery for stage 
T3N2M0 rectal cancer and had received postoperative 
concomitant radiotherapy and chemotherapy with 5-FU. 
The patient was administered chemotherapy with intra-
venous 5-FU 750 mg/day for 4 days in 1 month, and six 
cycles of chemotherapy at 1-month intervals were planned. 
After the third chemotherapy cycle, radiotherapy was 
added with 180 cGy/day for 28 days to give a cumulative 
dose of 5,040 cGy. However, skin lesions developed at 
the end of the twenty-sixth radiotherapy  session, after 
4,680 cGy, and 13 days after the fourth chemotherapy 
cycle. Physical examination revealed variously sized 
targetoid papules and confluent macules that initially 
developed on both buttocks, an irradiated site, and 
subsequently spread to the dorsum of the hands and the 
ears (Fig. 1). Laboratory test results, including white cell 
counts, antinuclear antibody, immunoglobulin E, and 
kidney and liver functions, were within normal limits. A 
herpes virus immunoglobulin G test was positive, but an 
IgM test was negative. Histopathology of a skin biopsy 
from the buttocks showed vacuolar alterations in the basal 
layer, and mild inflammatory perivascular infiltration, 
including many eosinophils in the dermis, which was 
consistent with EM (Fig. 2). The patient ceased radio-
therapy and had symptomatic treatment. The lesions 
almost completely resolved after 2 weeks of treatment. 
The patient received a fifth cycle of chemotherapy with 
the same regimen, and 13 days later, EM recurred on the 
arms and legs (Fig. 3).  The patient refused further chemo-
therapy because of the skin reaction, and the lesions 
resolved with antihistamine and steroid treatments. No 
rash developed over 1 year and 9 months of follow-up.
The combination of radiotherapy and chemotherapy is a 
well known cause of EM. In the case of EM induced by 
phenytoin and radiation, the acronym “EMPACT” (ery-
thema multiforme associated with phenytoin and cranial 
radiation therapy) has been suggested
4. Clinically, it is 
similar to our case in several aspects. It does not have an 
immediate skin reaction after drug exposure. The lesion 
arose initially from an irradiated area and spread to other 
sites after administration. Then, after re-administration of 
the drug, EM recurred. It is suspected that the eruption 
requires several days for the accumulation of active 
metabolites or immune complexes rather than the parent 
compound.
The interaction of 5-FU with radiation induced EM in our EM after Radiotherapy with 5-FU Chemotherapy
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Fig. 1. At the first visit, erythematous targetoid papules and plaques were distributed on the buttocks (a, b), the dorsum of the hands 
(c), and the ears (d).
patient, and the pathological mechanism has several 
possible explanations. 5-FU is primarily eliminated by 
metabolism by dihydropyrimidine dehydrogenase. Although 
5-FU is not a substrate for hepatic drug-metabolizing 
cytochrome P450 (CYP) enzymes, this antimetabolite may 
interfere with the synthesis of CYPs. Synthesis of CYP2C9 
and CYP2C19, which are important in the metabolism of 
phenytoin, is decreased by 5-FU pre-treatment
5, which 
could explain why 5-FU-induced EM is associated with 
CYPs such as CYP2C9 and CYP2C19.
Furthermore, radiotherapy can enhance the primary 
antibody response, when administered shortly after 
immunization
6. This can be explained by hypothesizing 
that suppressor cells are depleted, allowing for greater 
clonal expansion of sensitized cells that are free of 
feedback inhibition
7. It is possible that radiotherapy 
preferentially impairs T-suppressor cells, thus allowing full 
development of a hypersensitivity reaction to the drug. 
Mediators induced by radiotherapy, such as kinins and 
histamine, could increase vascular permeability and 
facilitate entry of the new antigen into the circulation and 
induce an immune response
8. These theories may also 
explain the greater likelihood of a drug reaction to 5-FU in 
the presence of radiotherapy, especially in the radiation 
field, and suggests that an increase in sensitivity and 
decrease in the threshold in radiated tissue lead to a 
hypersensitivity reaction upon exposure to 5-FU.
In conclusion, we report a case of EM secondary to the J H  H a n ,  e t  a l
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Fig. 2. Skin biopsy showing vacuolar changes in the basal layer,
and mild perivascular inflammatory cells, including many 
eosinophils, infiltrating in the dermis (H&E, ×100).
Fig. 3. Schematic representation of disease progression. After the
third cycle of 5-FU administration, radiotherapy was added to 
the treatment, and EM developed after the fourth administration
of 5-FU. Radiotherapy was stopped, and EM recurred following
the fifth administration of 5-FU. 5-FU: 5-fluorouracil, EM: 
erythma multiforme.
interaction of radiotherapy and chemotherapy with 5-FU 
in a rectal cancer patient. Clinicians should be aware of 
the rare potential for 5-FU and radiotherapy to cause EM.
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